Search

Displaying results 1501 - 1510 of 5449 in total
  1. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration. … [A249070] It is a taurine conjugate of [ursodeoxycholic acid] [A249065] with comparable therapeutic efficacy and safety,[A249070] but a much higher hydrophilicity.

    Products: TAUROLITE 250 MG 100 KAPSUL
  2. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L40026] It received subsequent approval for the same indications in Canada in May 2022. … However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced

    Products: VABYSMO 6mg/0.05mL Solution for Intravitreal Injection
  3. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt

  4. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA app...

  5. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194,L51199] It is the first FDA-approved anti-CSF-1R antibody directed against inflammatory and fibrotic drivers in chronic graft-versus-host disease.[L51199] … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated

  6. Drug

    Zonisamide

    go.drugbank.com/drugs/DB00909
    ApprovedInvestigational

    In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] … [L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors

    Products: ZONISAHEXAL 25 MG HKP, ZONISAHEXAL 50 MG HKP
  7. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [L26661] It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.

  8. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    It also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.

  9. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification … [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

  10. Drug

    Aluminum chloride

    go.drugbank.com/drugs/DB11081
    ApprovedInvestigational

    When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. … It may also be found in over-the-counter as an antiperspirant or prescription products as an antihemorrhagic agent.